Shanghai United Imaging Healthcare (688271) investor relations material

Executive summary

• Revenue for H1 2026 reached RMB 7.05 billion, up 17.22% year-over-year, with net profit attributable to shareholders at RMB 897 million, down 10.12% year-over-year, mainly due to foreign exchange losses and increased R&D and global expansion investments.

• All product lines achieved revenue growth; domestic market share increased by 1.7 percentage points despite a market slowdown, and overseas revenue grew over 50%, now accounting for 25.02% of total revenue.

• High-end and innovative products drove growth, with significant breakthroughs in MRI, CT, molecular imaging, and radiotherapy segments, and continued expansion in global markets.

Financial highlights

• Operating income: RMB 7.05 billion, up 17.22% year-over-year.

• Net profit attributable to shareholders: RMB 897 million, down 10.12% year-over-year.

• Operating cash flow: -RMB 242 million, compared to RMB 49 million in the prior year, due to increased business activity and cash outflows.

• Gross margin for Q2: 47.19%, with sequential improvement.

• R&D investment: RMB 1.38 billion, up 21.31% year-over-year, representing 19.61% of revenue.

• Basic and diluted EPS: RMB 1.10, down 9.09% year-over-year.

Outlook and guidance

• Management expects continued high-quality growth, driven by high-end product launches, global market expansion, and increased R&D investment.

• Anticipates further improvement in profitability as overseas business scales and high-end products gain market share.

• Focus on strengthening domestic and international market positions, with emphasis on innovation and customer value.